Drug Proving of homoeopathic drug substance on healthy volunteers to elicit the effect of the drug on the health status.

Homoeopathic Pathogenetic Trial of Drug Code 167: A Multicentre, double blind, randomized placebo controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/107924

Enrollment

Registered

2026-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Drug code 167: To be administered in 30C, 200C and 1M potencies. 12 doses for each potency, frequency- four times a day for a maximum of 3 days, route of administration- oral. Control I

Eligibility

Inclusion criteria

Inclusion criteria: Age : 18 to 60 years. Both males and females. Healthy individuals with no apparent disease and normal routine laboratory parameters during screening. Intelligent enough to record carefully the facts, subjective and objective symptoms generated by the drug during proving. Able to be informed of the nature of the study and willing to give written informed consent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The pathogenetic effect of Drug Code 167 in form of signs and/or symptoms.Timepoint: At baseline and at the end of the trial.	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Pritha Mehra

Central Council for Research in Homoeopathy

drpritha@gmail.com9999036871

Outcome results